Safety and pharmacokinetics of Alpha-1 MP (Prolastin®-C) in Japanese patients with alpha1-antitrypsin (AAT) deficiency.

[1]  M. Campos,et al.  Bioequivalence of a Liquid Formulation of Alpha1-Proteinase Inhibitor Compared with Prolastin®-C (Lyophilized Alpha1-PI) in Alpha1-Antitrypsin Deficiency , 2017, COPD.

[2]  M. Miravitlles,et al.  Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide , 2017, International journal of chronic obstructive pulmonary disease.

[3]  M. Miravitlles,et al.  Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update , 2017, International journal of chronic obstructive pulmonary disease.

[4]  C. Mueller,et al.  Alpha-1 Antitrypsin Deficiency , 2017, Methods in Molecular Biology.

[5]  M. Nishimura,et al.  A nationwide epidemiological survey of alpha1-antitrypsin deficiency in Japan. , 2016, Respiratory investigation.

[6]  D. Lomas,et al.  α1-antitrypsin deficiency , 2005, The Lancet.

[7]  M. Campos,et al.  Safety and Pharmacokinetics of 120 mg/kg versus 60 mg/kg Weekly Intravenous Infusions of Alpha-1 Proteinase Inhibitor in Alpha-1 Antitrypsin Deficiency: A Multicenter, Randomized, Double-Blind, Crossover Study (SPARK) , 2013, COPD.

[8]  R. Abboud,et al.  Alpha1-antitrypsin deficiency: a clinical-genetic overview , 2011, The application of clinical genetics.

[9]  M. Campos,et al.  Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha1-antitrypsin deficiency: a randomized study , 2010, BMC clinical pharmacology.

[10]  M. Campos,et al.  Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency , 2009 .

[11]  Peter C Gøtzsche,et al.  Alpha1-antitrypsin deficiency. , 2009, The New England journal of medicine.

[12]  M. Pistolesi,et al.  Outcomes for COPD pharmacological trials: from lung function to biomarkers , 2008, European Respiratory Journal.

[13]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[14]  M. Schluchter,et al.  Clinical InvestigationsANTITRYPSINAugmentation Therapy With α1-Antitrypsin: Patterns of Use and Adverse Events , 2003 .

[15]  R. S. Sen,et al.  Survival and FEV1 decline in individuals with severe deficiency of α1-antitrypsin , 1998 .

[16]  N. Banik,et al.  Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. , 1997, The European respiratory journal.

[17]  M. Schluchter,et al.  Baseline Characteristics of Enrollees in the National Heart, Lung and Blood Institute Registry of α1-Antitrypsin Deficiency , 1997 .

[18]  S. Kira,et al.  Alpha 1-antitrypsin-deficient variant Siiyama (Ser53[TCC] to Phe53[TTC]) is prevalent in Japan. Status of alpha 1-antitrypsin deficiency in Japan. , 1995, American journal of respiratory and critical care medicine.

[19]  S. Kira,et al.  Siiyama (serine 53 (TCC) to phenylalanine 53 (TTC)). A new alpha 1-antitrypsin-deficient variant with mutation on a predicted conserved residue of the serpin backbone. , 1991, The Journal of biological chemistry.

[20]  R. Crystal,et al.  Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. , 1990, The Journal of clinical investigation.

[21]  R. Crystal,et al.  Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. , 1987, The New England journal of medicine.

[22]  R. Crystal,et al.  Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. , 1981, The Journal of clinical investigation.